Health Condition 1: L401- Generalized pustular psoriasis
Conditions
Interventions
Intervention1: NalpamaradiTaila (Ref: Sahasrayoga AFI - I, API Part II, Vol - III)
: Dose: 20ml BD
Dosage form : Oil
Route of Administration : External application
Time of Administration : T
Sponsors
Central Council for Research in Ayurvedic Sciences CCRAS
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either sex with age between 18 and 60 years. 2. Known cases of psoriasis, without psoriatic arthropathy, Exhibiting psoriatic triad â?? a. Bright pink or red lesions with pronounced edges, covered with silvery white scales, the scales can be easily separated from the lesion. b. Under the scales there appears a pinkish moist tender skin. c. With the scraping of the moist skin there appear tiny blood droplets (Auspitzâ??s sign) 3. Patients suffering from psoriasis with less than 50 % of the body surface involvement. 4. Disease duration between 3 months to 5 years. 5. V.D.R.L./ HIV/Hepatitis negative. 6. Positive histopathological finding.(Skin-biopsy) 7. Willing to participate in the study
Exclusion criteria
Exclusion criteria: 1. Generalized skin lesions, Herpes simplex, Herpes zoster, Scabies, Acne, Urticaria, and Immunological medicated skin diseases like Pempigus vulgaris, Dermatitis,herpetiformis, Guttate, Pustular, Lupus erythematous, Psoriatic arthropathy etc. 2. Patients with poorly controlled Hypertension (Blood pressure more than 160/100mm of Hg). 3. Pregnant or lactating women. 4. Patient with uncontrolled Diabetes Mellitus (Blood sugar fasting more than 250 mg/dl). 5. Patient suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, cardiovascular disease Tuberculosis, Psycho - Neuro-endocrinal disorders, etc.). 6. Patients on medication with corticosteroids, phototherapy, biologics,antidepressants any other drugs that may have an influence on the outcome of the study. 7. Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT >3 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.4 mg/dl) oruncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) or AIDS or STD or other concurrent severe disease. 8. Alcoholics and/or drug abusers. 9. H/o hypersensitivity to the trial drug or any of its ingredients. 10. Patients who have completed participation in any other clinical trial during the past six months. 11. Any other condition which the Investigator thinks may jeopardize the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in Psoriasis Area and Severity Index(PASI) scoreTimepoint: 84 day | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the clinical Sign & symptoms ofPsoriasis Change in Dermatology life Quality Index (DLQI) Questionnaire Timepoint: 84 day | — |
Countries
India
Contacts
Public ContactDrAminHetalben
Central Council for Research in Ayurvedic Sciences (C.C.R.A.S.)
Outcome results
None listed